Ponesimod maintains low disease activity and safety in RRMS over 13 years
Trial Shows Ponesimod Maintains Safety for Relapsing-Remitting Multiple Sclerosis
This Phase 2b randomized controlled trial of 393 participants with relapsing-remitting multiple sclerosis found that ponesimod (10, 20, or 4…
A clinical trial shows that patients with relapsing-remitting multiple sclerosis can stay on ponesimod for up to 13 years with consistent re…
Ponesimod Shows Sustained Efficacy and Safety in RMS Over 5 Years
Could Ponesimod Change the Game for Multiple Sclerosis Patients?
In a 5-year extension of the OPTIMUM study, ponesimod 20 mg maintained a lower ARR (0.143) compared to teriflunomide switchers (0.184).
After five years, nearly half of people taking ponesimod for multiple sclerosis had no relapses, offering more stable lives with fewer unexp…